Cara Therapeutics announces completion of interim statistical assessment
Cara Therapeutics announced completion of an interim statistical assessment of its pivotal KALM-2 Phase 3 global clinical trial of KORSUVA™ (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus. October 14, 2019